Previous studies have demonstrated that the expression of VANGL2 is significantly downregulated in several cancer cell lines and primary tumors, and a low expression of VANGL2 is associated with a significantly worse clinical outcome in neuroblastoma (9–11). This evidence concerns the gene VANGL2 and neuroblastoma.